Dexamethasone inhibits insulin-stimulated recruitment of GLUt4 to the cell surface in rat skeletal muscle

Weinstein, S.; Wilson, C M; Pritsker, Alla; Cushman, Samuel W.

doi:10.1016/s0026-0495(98)90184-6

Cited by 135 publications

(110 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings provide confirmation of previous studies demonstrating that glucocorticoids induce peripheral insulin resistance (2-4) in healthy humans, and they show a pronounced effect of steroids to decrease maximal insulin responsiveness, which was not clearly evident in a previous report (2). This reflects impaired stimulation of glucose uptake in skeletal muscle, which has been shown to result from defects in the recruitment of GLUT4 glucose transporters to the cell surface in animal (12,13) and cell (14 -17) models. Peripheral insulin resistance, together with insulin resistance at the level of the liver (2-4), leads to impaired glucose tolerance, as manifested in the current data by higher glucose and insulin concentrations after an oral glucose challenge.…”

Section: Discussionsupporting

confidence: 91%

“…Studies in animals (5-8) as well as humans (1)(2)(3)(4)9) have shown that glucocorticoid excess results in decreased insulin-stimulated glucose uptake in muscle, and this occurs in the absence of any consistent effect on insulin receptor number or ligand affinity (5,10,11). Additional studies in rodent skeletal muscle indicate that glucocorticoid administration disrupts insulin-mediated recruitment of glucose transporters to the cell surface, without affecting expression of the insulin-responsive GLUT4 transporter isoform (12,13). In cultured cells (14 -16), dexamethasone treatment acutely impairs glucose transporter translocation in response to insulin and, with more chronic exposure, reduces basal glucose transport activity associated with decreased expression of GLUT1 transporters (17).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans

et al. 2002

View full text Add to dashboard Cite

Glucocorticoids induce insulin resistance in humans, whereas thiazolidinediones enhance insulin sensitivity. Although the effects of glucocorticoids and thiazolidinediones have been assessed in isolation, interaction between these drugs, which both act as ligands for nuclear receptors, has been less well studied. Therefore, we examined the metabolic effects of dexamethasone and troglitazone, alone and in combination, for the first time in humans. A total of 10 healthy individuals with normal glucose tolerance (age 40 ؎ 11 years, BMI 31 ؎ 6.1 kg/m 2) were sequentially studied at baseline, after 4 days of dexamethasone (4 mg/day), after 4 -6 weeks on troglitazone alone (400 mg/day), and again after 4 days of dexamethasone added to troglitazone. Key metabolic variables included glucose tolerance assessed by blood glucose and insulin responses to an oral glucose tolerance test (OGTT), insulin sensitivity evaluated via hyperinsulinemic-euglycemic clamp, free fatty acids (FFAs) and FFA suppressibility by insulin during the clamp study, and fasting serum leptin. Dexamethasone drastically impaired glucose tolerance, with fasting and 2-h OGTT insulin values increasing by 2.3-fold (P < 0.001) and 4.4-fold (P < 0.001) over baseline values, respectively. The glucocorticoid also induced a profound state of insulin resistance, with a 34% reduction in maximal glucose disposal rates (GDRs; P < 0.001). Troglitazone alone increased GDRs by 20% over baseline (P ‫؍‬ 0.007) and completely prevented the deleterious effects of dexamethasone on glucose tolerance and insulin sensitivity, as illustrated by a return of OGTT glucose and insulin values and maximal GDR to near-baseline levels. Insulin-mediated FFA suppressibility (FFA decline at 30 min during clamp/FFA at time 0) was also markedly reduced by dexamethasone (P ‫؍‬ 0.002). Troglitazone had no effect per se, but it was able to normalize FFA suppressibility in subjects coadministered dexamethasone. Futhermore, the magnitudes of response of FFA suppressibility and GDR to dexamethasone were proportionate. The same was true for the reversal of dexamethasone-induced insulin resistance by troglitazone, but not in response to troglitazone alone. Leptin levels were increased 2.2-fold above baseline by dexamethasone. Again, troglitazone had no effect per se but blocked the dexamethasone-induced increase in leptin. Subjects experienced a 1.7-kg weight gain while taking troglitazone but no other untoward effects. We conclude that in healthy humans, thiazolidinediones antagonize the action of dexamethasone with respect to multiple metabolic effects. Specifically, troglitazone reverses both glucocorticoid-induced insulin resistance and impairment of glucose tolerance, prevents dexamethasone from impairing the antilipolytic action of insulin, and blocks the increase in leptin levels induced by dexamethasone. Even though changes in FFA suppressibility were correlated with dexamethasone-induced insulin resistance and its reversal by troglitazone, a cause-and-effect relationship cannot be establ...

show abstract

Section: Discussionsupporting

confidence: 91%

mentioning

confidence: 99%

Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Similar observations were reported in primarily cultured adipocytes (11). Insulin-stimulated recruitment of GLUT4 to the cell surface is also reportedly inhibited by dexamethasone in muscle and adipose tissue (12).…”

supporting

confidence: 81%

Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction.

et al. 2000

View full text Add to dashboard Cite

Glucocorticoids reportedly induce insulin resistance. In this study, we investigated the mechanism of glucocorticoid-induced insulin resistance using 3T3-L1 adipocytes in which treatment with dexamethasone has been shown to impair the insulin-induced increase in glucose uptake. In 3T3-L1 adipocytes treated with dexamethasone, the GLUT1 protein expression level was decreased by 30%, which possibly caused decreased basal glucose uptake. On the other hand, dexamethasone treatment did not alter the amount of GLUT4 protein in total cell lysates but decreased the insulin-stimulated GLUT4 translocation to the plasma membrane, which possibly caused decreased insulin-stimulated glucose uptake. Dexamethasone did not alter tyrosine phosphorylation of insulin receptors, and it significantly decreased protein expression and tyrosine phosphorylation of insulin receptor substrate (IRS)-1. Interestingly, however, protein expression and tyrosine phosphorylation of IRS-2 were increased. To investigate whether the reduced IRS-1 content is involved in insulin resistance, IRS-1 was overexpressed in dexamethasone-treated 3T3-L1 adipocytes using an adenovirus transfection system. Despite protein expression and phosphorylation levels of IRS-1 being normalized, insulin-induced 2-deoxy-D-[ 3 H]glucose uptake impaired by dexamethasone showed no significant improvement. Subsequently, we examined the effect of dexamethasone on the glucose uptake increase induced by overexpression of GLUT2-tagged p110␣, constitutively active Akt (myristoylated Akt), oxidative stress (30 mU glucose oxidase for 2 h), 2 mmol/l 5-aminoimidazole-4-carboxamide ribonucleoside for 30 min, and osmotic shock (600 mmol/l sorbitol for 30 min). Dexamethasone treatment clearly inhibited the increases in glucose uptake produced by these agents. Thus, in conclusion, the GLUT1 decrease may be involved in the dexamethasone-induced decrease in basal glucose transport activity, and the mechanism of dexamethasone-induced insulin resistance in glucose transport activity (rather than the inhibition of phosphatidylinositol 3-kinase activation resulting from a decreased IRS-1 content) is likely to underlie impaired glucose transporter regulation.

show abstract

“…The inhibitory effect on post-receptor insulin signaling is then also translated into impaired glucose uptake by the glucose transporter 4 (Glut4). Insulinstimulated re-location of Glut4 to the plasma membrane is efficiently inhibited by GC exposure [179][180][181][182], representing a physiological rational for GC-induced glucose intolerance and hyperglycemia as hallmarks of the Metabolic Syndrome. Consistently, adipose-specific ablation of Glut4 leads to impaired glucose tolerance and insulin sensitivity in mice [183].…”

Section: Lipolytic Functions Of Gcsmentioning

confidence: 99%

“…Thus, a central aspect of GC-induced insulin resistance in muscle resides in the suppression of glucose uptake mainly through inhibited translocation of the glucose transporter Glut4 to the cell surface (Fig. 3) [180,227]. Furthermore, GC treatment results in reduced glycogen synthesis through a mechanism involving suppression of glycogen synthase activity [228,229].…”

Section: Effects Of Gcs On Glucose and Protein Metabolism: Molecular mentioning

confidence: 99%

Glucocorticoids, metabolism and metabolic diseases

Vegiopoulos

Herzig

2007

Molecular and Cellular Endocrinology

448

370

View full text Add to dashboard Cite

Since the discovery of the beneficial effects of adrenocortical extracts for treating adrenal insufficiency more than 80 years ago, glucocorticoids (GC) and their cognate, intracellular receptor, the glucocorticoid receptor (GR) have been characterized as critical components of the delicate hormonal control system that determines energy homeostasis in mammals.Whereas physiological levels of GCs are required for proper metabolic control, excessive GC action has been tied to a variety of pandemic metabolic diseases, such as type II diabetes and obesity. Highlighted by its importance for human health, the investigation of molecular mechanisms of GC/GR action has become a major focus in biomedical research. In particular, the understanding of tissue-specific functions of the GC-GR pathway has been proven to be of substantial value for the identification of novel therapeutic options in the treatment of severe metabolic disorders. Therefore, this review focuses on the role of the GC-GR axis for metabolic homeostasis and dysregulation, emphasizing tissue-specific functions of GCs in the control of energy metabolism.

show abstract

Dexamethasone inhibits insulin-stimulated recruitment of GLUt4 to the cell surface in rat skeletal muscle

Cited by 135 publications

References 8 publications

Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans

Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans

Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction.

Glucocorticoids, metabolism and metabolic diseases

Contact Info

Product

Resources

About